Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Wright

Showing results (61-70 of 63) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 63 results.
Journal of Cardiac Failure|May 13, 2026
Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM TrialAmrut V Ambardekar, Nitasha Sarswat, Richard Wright, et al.
JAMA Cardiology|March 30, 2026
Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical TrialPrem Soman, Sarah A M Cuddy, Julian D Gillmore, et al.
JAMA Cardiology|November 8, 2025
Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label ExtensionKevin M Alexander, Margot K Davis, Olakunle Akinboboye, et al.
Pageof 7

Showing results (61-70 of 63) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 63 results.
Journal of Cardiac Failure|May 13, 2026
Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM TrialAmrut V Ambardekar, Nitasha Sarswat, Richard Wright, et al.
JAMA Cardiology|March 30, 2026
Long-Term Durability of Acoramidis Efficacy in Transthyretin Amyloid Cardiomyopathy: Open-Label Extension of the ATTRibute-CM Randomized Clinical TrialPrem Soman, Sarah A M Cuddy, Julian D Gillmore, et al.
JAMA Cardiology|November 8, 2025
Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label ExtensionKevin M Alexander, Margot K Davis, Olakunle Akinboboye, et al.
Pageof 7